Paraoxonase activity and antibodies to oxidized-LDL in chronic renal failure patients on renal replacement therapy

被引：5
作者：
Krishnaswamy P.R. [2 ]
Rao A. [1 ]
Murali W. [2 ,3 ]
Ballal H.S. [2 ]
机构：
[1] Department of Biochemistry, Kasturba Medical College, Manipal, Karnataka
[2] Manipal Hospital, Bangalore, Karnataka
[3] Manipal Hospital, Banglore-560 003, No.98, Rustom bagh, Airport Road
来源：
Indian Journal of Clinical Biochemistry | 2006年 / 21卷 / 2期
关键词：
Atherosclerosis; Dialysis; HDL-cholesterol; Oxidative stress; Transplantation;
D O I：
10.1007/BF02912937
中图分类号：
学科分类号：
摘要：
Serum paraoxonase (PON1) and antibodies to oxidized-LDL (anti ox-LDL) were measured in chronic renal failure subjects on renal replacement therapy such as hemodialysis (HD) peritoneal dialysis (PD) and transplantation (Txp). Paraoxonase activity was significantly lower in HD and PD group (P<0.001) than in control subjects. In transplant patients, paraoxonase activity was not significantly different from that of controls. Antibodies to ox-LDL was significantly higher in HD, PD and Transplant patients (P<0.0001) compared to control subjects. High titers of antibodies were observed in the HD group compared to the PD and Transplant subjects. A decrease in paraoxonase activity and high titers of Antibodies to ox-LDL in the dialysis group suggest a decreased cardio protective effect of HDL and enhanced risk of premature cardiovascular complications. Whereas in case of transplant subjects, there seems to be restoration of PON1 activity, but elevated levels of anti-oxLDL could still be a potential atherogenic factor. Hence, we propose that estimation of these two parameters can be used as a useful index to measure the cardiac risk in the above patient category.
引用
收藏
页码：173 / 176
页数：3
相关论文
共 21 条
  • [1] Durrington P.N., Arrol S., Mackness M.I., Paraoxonase prevents accumulation of lipoperoxidase in low-density lipoprotein, FEBS Lett., 286, pp. 152-154, (1991)
  • [2] Mackness M.I., Abbott C.A., Arrol S., Durrington P.N., The role of High density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation, Biochem. J., 294, pp. 829-835, (1993)
  • [3] Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M., Protective effect of high density lipoprotein associated paraoxonase, J. Clin. Invest., 96, pp. 2882-2891, (1995)
  • [4] Schiavon R., De Fanti E., Giavarina D., Biasioli S., Cavalcanti G., Guidi G., Serum paraoxonase activity decreased in uremic patients, Clin. Chim. Acta, 247, pp. 71-80, (1996)
  • [5] Gyorgy P., Laszlo A., Iidiko S., Zoltan B., Lajos L., Gyorgy K., Serum paraoxonase activity changes in uremic and kidney transplanted patients, Nephron, 83, pp. 126-131, (1991)
  • [6] Witztum J.L., Steinberg D., Role of oxidized low-density lipoprotein in atherogenesis, J. Clin. Invest., 88, pp. 1785-1792, (1991)
  • [7] Maggi E., Bellazzi R., Falaschi F., Frattoni A., Perani G., Et al., Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?, Kidney Int., 45, pp. 876-883, (1994)
  • [8] Haagen L., Brock A., A new automated method for phenotyping arylesterase based upon inhibition of enzymatic hydrolysis of 4-nitrophenlyacetate by phenyl acetate, Eur. J. Clin. Chem. Clin. Biochem., 30, pp. 391-395, (1992)
  • [9] Chait A., Brazg R., Tribble D., Krauss R., Susceptibility of small, dense, low- Density Lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B, Am. J. Med., 94, pp. 350-356, (1993)
  • [10] Aviram M., Rosenblat M., Billecke S., Et al., Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants, Free Radic. Biol. Med., 26, pp. 892-904, (1999)
123